Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acarbose in abnormal glucose tolerance with coronary artery disease
NCT00221156Phase 3Completed
- Sponsor
- Translational Research Center for Medical Innovation
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acarbose in impaired glucose tolerance (IGT) (2 arms), sponsored by Translational Research Center for Medical Innovation. Primary endpoint: Cardiovascular event free survival time. Started May 2005; status: completed.
02
Drugs
acarbose
03
Conditions
impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT00221156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00221156.